GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 8,860.00
-240.00 (-2.64%)
At close: Feb 6, 2026
GC Genome Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 30,789 | 25,888 | 27,292 | 24,114 | 18,498 | 13,556 |
Other Revenue | - | - | - | - | -0 | - |
| 30,789 | 25,888 | 27,292 | 24,114 | 18,498 | 13,556 | |
Revenue Growth (YoY) | 12.81% | -5.15% | 13.18% | 30.36% | 36.46% | 11.51% |
Cost of Revenue | 16,717 | 14,181 | 13,595 | 13,349 | 11,318 | 7,457 |
Gross Profit | 14,072 | 11,707 | 13,697 | 10,765 | 7,180 | 6,099 |
Selling, General & Admin | 6,276 | 6,464 | 5,791 | 5,564 | 4,204 | 2,996 |
Research & Development | 6,222 | 6,053 | 7,355 | 8,121 | 4,841 | 2,948 |
Amortization of Goodwill & Intangibles | 40.65 | 37.75 | 35.12 | 36.26 | 29.1 | 26.75 |
Other Operating Expenses | 50.36 | 54.31 | 46.41 | 47.85 | 17.65 | 18.08 |
Operating Expenses | 12,939 | 12,940 | 13,537 | 14,000 | 9,289 | 6,102 |
Operating Income | 1,133 | -1,234 | 160.08 | -3,236 | -2,109 | -2.73 |
Interest Expense | -329.61 | -959.77 | -920.67 | -1,695 | -1,482 | -119.99 |
Interest & Investment Income | 1,603 | 1,059 | 482.41 | 508.99 | 297 | 40.74 |
Currency Exchange Gain (Loss) | 447.32 | 882.39 | -83.19 | -160.36 | -12.42 | 2.25 |
Other Non Operating Income (Expenses) | 229.65 | 248.44 | -454.79 | 756.59 | 3,727 | 42.54 |
EBT Excluding Unusual Items | 3,084 | -3.2 | -816.17 | -3,826 | 420.4 | -37.18 |
Gain (Loss) on Sale of Investments | - | - | - | -2.93 | - | - |
Gain (Loss) on Sale of Assets | 3.66 | 1.37 | 1.57 | -44.89 | -13.83 | -0.29 |
Asset Writedown | -436.19 | -1,125 | - | - | - | - |
Pretax Income | 2,651 | -1,127 | -814.6 | -3,874 | 406.57 | -37.47 |
Income Tax Expense | 209.55 | 129.84 | -264.5 | -110.52 | 113.37 | -34.8 |
Net Income | 2,441 | -1,257 | -550.1 | -3,763 | 293.2 | -2.67 |
Net Income to Common | 2,441 | -1,257 | -550.1 | -3,763 | 293.2 | -2.67 |
Shares Outstanding (Basic) | 21 | 18 | 18 | 16 | 16 | 18 |
Shares Outstanding (Diluted) | 21 | 18 | 18 | 16 | 16 | 18 |
Shares Change (YoY) | 12.73% | -0.66% | 13.53% | 0.97% | -10.25% | 90.88% |
EPS (Basic) | 118.11 | -69.00 | -30.00 | -233.00 | 18.33 | -0.15 |
EPS (Diluted) | 118.11 | -69.00 | -30.00 | -233.00 | 18.33 | -0.15 |
Free Cash Flow | 410.95 | 49.4 | -4,065 | -5,639 | -2,935 | -1,747 |
Free Cash Flow Per Share | 19.88 | 2.71 | -221.71 | -349.17 | -183.51 | -98.03 |
Gross Margin | 45.70% | 45.22% | 50.19% | 44.64% | 38.81% | 44.99% |
Operating Margin | 3.68% | -4.76% | 0.59% | -13.42% | -11.40% | -0.02% |
Profit Margin | 7.93% | -4.86% | -2.02% | -15.61% | 1.58% | -0.02% |
Free Cash Flow Margin | 1.33% | 0.19% | -14.90% | -23.39% | -15.87% | -12.89% |
EBITDA | 4,094 | 1,986 | 3,701 | -429 | -51.89 | 978.26 |
EBITDA Margin | 13.30% | 7.67% | 13.56% | -1.78% | -0.28% | 7.22% |
D&A For EBITDA | 2,961 | 3,219 | 3,541 | 2,807 | 2,057 | 980.99 |
EBIT | 1,133 | -1,234 | 160.08 | -3,236 | -2,109 | -2.73 |
EBIT Margin | 3.68% | -4.76% | 0.59% | -13.42% | -11.40% | -0.02% |
Effective Tax Rate | 7.90% | - | - | - | 27.88% | - |
Advertising Expenses | - | 90.12 | 143.22 | 148.84 | 97.65 | 94.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.